课题基金 / 基金详情

DNA double-strand break repair, chromosomes translocations and cancer

DNA double-strand break repair, chromosomes translocations and cancer
DNA 双链断裂修复、染色体易位和癌症
批准号:
8608844
负责人:
JEAN GAUTIER
金额:
$177.86万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-08 至 2019-03-31

项目摘要

项目成果

JEAN GAUTIER的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):DNA双链断裂(DSB)修复可防止持续性DNA损伤,抵消基因组不稳定性并抑制肿瘤发展。然而,DSB修复也有可能产生致癌染色体易位和重排。这个高度整合的项目将阐明DSB修复启动的机制和调控及其对淋巴瘤和乳腺癌模型中DSB修复选择、染色体易位和癌症发展的影响。特别是,该计划将研究微同源介导的末端连接(MMEJ)的调节,这是一种致病形式的DSB修复,负责致瘤性染色体易位的重要部分。所有项目的初步研究都集中在DNA处理和CtIP上,已经产生了一个有重点和有凝聚力的计划。Symington博士将使用遗传分析来评估DNA切除如何影响MMEJ,并调查MMEJ与其他DSB修复模式之间的竞争。Symington博士还将在哺乳动物细胞中开发敏感的物理切除试验,这是目前明显缺乏的技术。Gautier和Gottesman博士将研究在DSB上产生持久的短ssDNA突出端的机制,DSB是参与MMEJ的中间体。他们的研究将集中在CtIP的作用上,CtIP是一种参与启动DNA切除的蛋白质。在第三个项目中,Zha博士和Dalla-Favera博士将评估 CtIP在淋巴细胞发育和恶性肿瘤过程中修复程序性DSB中的作用。他们还将检验CtIP至少部分介导c-Myc的致癌功能的假设,包括其在基因组不稳定性中的不确定作用。Baer博士将确定CtIP如何促进p53缺陷小鼠的乳腺肿瘤发展,并将测试CtIP丢失是否也可以抑制BRCA 1缺陷小鼠的基底样乳腺癌。最后,他将评估CtIP在Myc驱动的乳腺肿瘤发展中的潜在作用。为了实现这些目标,这些项目将广泛依赖于三个相互关联的核心:行政、基因组不稳定性的分子分析和病理学。该项目和核心领导人有着很强的合作历史,在培训方面的共同努力以及在基因组稳定性及其在癌症中丢失的机制方面的共同利益。
英文摘要
DESCRIPTION (provided by applicant): DNA double-strand break (DSB) repair prevents persistent DNA damage, counteracts genome instability and suppresses tumor development. However, DSB repair also has the potential to produce oncogenic chromosome translocations and rearrangements. This highly integrated program will elucidate the mechanism and regulation of DSB repair initiation and its impact on DSB repair choice, chromosome translocation and cancer development in model of lymphoma and breast cancer. In particular, the program will investigate the regulation of microhomology-mediated end-joining (MMEJ), a pathogenic form of DSB repair responsible for a significant fraction of tumorigenic chromosome translocations. Preliminary studies from all projects focusing on DNA processing and CtIP have generated a focused and cohesive program. Dr. Symington will use genetic analysis to assess how DNA resection affects MMEJ and to investigate the competition between MMEJ and other modes of DSB repair. Dr. Symington will also develop sensitive physical resection assays in mammalian cells, a technology which is notably lacking at present. Drs. Gautier and Gottesman will study the mechanism(s) that generate persistent, short ssDNA overhangs at DSBs, an intermediate involved in MMEJ. Their studies will focus on the role of CtIP, a protein involved in initiation of DNA resection. In the third project, Drs. Zha and Dalla-Favera will evaluate the role of CtIP in repair of programmed DSBs during lymphocyte development and malignancy. They will also test the hypothesis that CtIP mediates, at least in part, the oncogenic function of c-Myc including its undefined role in genomic instability. Dr. Baer, will determine how CtIP facilitates breast tumor development in p53-deficient mice and will test whether CtIP loss can also suppress basal-like breast cancer in BRCA1-deficient mice. Finally, he will evaluate the potential role of CtIP in Myc-driven breast tumor development. To accomplish these goals, the projects will rely extensively on three interlinked cores: administrative, molecular analysis of genomic instability and pathology. The project and core leaders have a very strong history of collaboration, joint efforts in training and common interests in genome stability and the mechanisms of its loss in cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DNA Repair and Genomic Instability in Cancer Development and Therapy
DNA Repair and Genomic Instability in Cancer Development and Therapy
DNA Repair and Genomic Instability in Cancer Development and Therapy
DNA Repair and Genomic Instability in Cancer Development and Therapy
海外基金